Evicenter
Mounjaro (tirzepatide) in Type 2 diabetes
Manufacturer
Lilly USA, LLC
Prescribing information
Mounjaro (opens in a new tab)
Questions
37
Last updated

All questions

Clinical trials: Mounjaro (tirzepatide) in type 2 diabetes

13 questions · 3 sources

Study results

How much does Mounjaro lower A1C in type 2 diabetes trials?

“Panel of bar charts showing the mean change in A1C from baseline for pediatric and adult patients with type 2 diabetes. SURPASS-PEDS studied Mounjaro as add-on to metformin and/or basal insulin vs placebo over 30 weeks in pediatric patients 10 years of age and older with type 2 diabetes. The mean baseline A1C was 8.2%, 7.9%, 8.1%, and 8.0% for Mounjaro 5 mg, Mounjaro 10 mg, pooled Mounjaro (5 mg and 10 mg), and placebo, respectively. Patients in the Mounjaro 5 mg group (n=32) had a -1.9% change from baseline. Patients in the Mounjaro 10 mg group (n=33) had a -2.2% change from baseline. Patients in the pooled Mounjaro group (n=65) had a -2.0% change from baseline. Patients in the placebo group (n=34) had a -0.2 percent change from baseline. SURPASS-1 through -5 evaluated the mean change in A1C from baseline in adult patients with type 2 diabetes. SURPASS-1 studied Mounjaro monotherapy vs placebo over 40 weeks. The mean baseline A1C was 8.0%, 7.9%, 7.9%, and 8.1% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients in the Mounjaro 5 mg group (n=121) had a -1.8% change from baseline. Patients in the Mounjaro 10 mg group (n=121) had a -1.7% change from baseline. Patients in the Mounjaro 15 mg group (n=120) had a -1.7% change from baseline. Patients in the placebo group (n=113) had a -0.1 percent change from baseline. SURPASS-2 studied Mounjaro as an add-on to metformin vs Ozempic 1 mg over 40 weeks. Ozempic 2 mg injection was not available at the time of the study. The mean baseline A1C was 8.3% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Ozempic 1 mg. Patients taking Mounjaro 5 mg (n=470) had a -2.0% change from baseline. Patients taking Mounjaro 10 mg (n=469) had a -2.2% change from baseline. Patients taking Mounjaro 15 mg (n=469) had a -2.3% change from baseline. Patients taking Ozempic 1 mg (n=468) had a -1.9% change from baseline. SURPASS-3 studied Mounjaro as an add-on to metformin plus or minus a sodium-glucose cotransporter-2 inhibitor vs Tresiba over 52 weeks. The mean baseline A1C was 8.2%, 8.2%, 8.2%, and 8.1% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Tresiba, respectively. Patients taking Mounjaro 5 mg (n=358) had a -1.9% change from baseline. Patients taking Mounjaro 10 mg (n=360) had a -2.0% change from baseline. Patients taking Mounjaro 15 mg (n=358) had a -2.1% change from baseline. Patients taking Tresiba (n=359) had a -1.3% change from baseline. SURPASS-4 studied Mounjaro as an add-on to 1-3 oral antihyperglycemic medications (metformin, sulfonylurea, sodium-glucose cotransporter-2 inhibitor) vs insulin glargine over 52 weeks. The mean baseline A1C was 8.5%, 8.6%, 8.5%, and 8.5% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and insulin glargine, respectively. Patients taking Mounjaro 5 mg (n=328) had a -2.1% change from baseline. Patients taking Mounjaro 10 mg (n=326) had a -2.3% change from baseline. Patients taking Mounjaro 15 mg (n=337) had a -2.4% change from baseline. Patients taking insulin glargine (n=998) had a -1.4% change from baseline. SURPASS-5 studied Mounjaro as an add-on to basal insulin plus or minus metformin vs placebo over 40 weeks. The mean baseline A1C was 8.3%, 8.4%, 8.2%, and 8.4% for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=116) had a -2.1% change from baseline. Patients taking Mounjaro 10 mg (n=118) had a -2.4% change from baseline. Patients taking Mounjaro 15 mg (n=118) had a -2.3% change from baseline. Patients taking placebo (n=119) had a -0.9% change from baseline.” (opens the source at this quote in a new tab)

On the page, select: Image description

Note: The figure description does not mark which results carry footnotes d and e; the Prescribing Information tables for SURPASS-1 through -5 and SURPASS-PEDS give each difference from comparator with its 95% CI and p-value.

How much does Mounjaro alone lower A1C and weight vs placebo (SURPASS-1)?

Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

“Table 4: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Placebo MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N)a 113 121 121 120 HbA1c (%) Baseline (mean) 8.1 8.0 7.9 7.9 Change at Week 40b -0.1 -1.8 -1.7 -1.7 Difference from placebob (95% CI) -- -1.7c (-2.0, -1.4) -1.6c (-1.9, -1.3) -1.6c (-1.9, -1.3) Patients (%) achieving HbA1c <7%d 23 82c 85c 78c Fasting Serum Glucose (mg/dL) Baseline (mean) 155 154 153 154 Change at Week 40b 4 -40 -40 -39 Difference from placebob (95% CI) -- -43c (-55, -32) -43c (-55, -32) -42c (-54, -30) Body Weight (kg) Baseline (mean) 84.5 87.0 86.2 85.5 Change at Week 40b -1.0 -6.3 -7.0 -7.8 Difference from placebob (95% CI) -- -5.3c (-6.8, -3.9) -6.0c (-7.4, -4.6) -6.8c (-8.3, -5.4)” (opens the source at this quote in a new tab)

Note: Table 4 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

Mounjaro vs Ozempic 1 mg: which lowers A1C and weight more (SURPASS-2)?

Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

“Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.05 (two-sided) for superiority versus semaglutide, adjusted for multiplicity. d p<0.001 (two-sided) for superiority versus semaglutide, adjusted for multiplicity. e Analyzed using logistic regression adjusted for baseline value and other stratification factors. f p<0.01 (two-sided) for superiority versus semaglutide, adjusted for multiplicity. Semaglutide 1 mg MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N)a 468 470 469 469 HbA1c (%) Baseline (mean) 8.3 8.3 8.3 8.3 Change at Week 40b -1.9 -2.0 -2.2 -2.3 Difference from semaglutideb (95% CI) -- -0.2c (-0.3, -0.0) -0.4d (-0.5, -0.3) -0.5d (-0.6, -0.3) Patients (%) achieving HbA1c <7%e 79 82 86f 86f Fasting Serum Glucose (mg/dL) Baseline (mean) 171 174 174 172 Change at Week 40b -49 -55 -59 -60 Body Weight (kg) Baseline (mean) 93.7 92.5 94.8 93.8 Change at Week 40b -5.7 -7.6 -9.3 -11.2 Difference from semaglutideb (95% CI) -- -1.9c (-2.8, -1.0) -3.6d (-4.5, -2.7) -5.5d (-6.4, -4.6)” (opens the source at this quote in a new tab)

Note: Table 5 columns are semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order. The Mounjaro HCP site names the SURPASS-2 comparator Ozempic 1 mg. These results apply to SURPASS-2 and its semaglutide 1 mg dose only.

Mounjaro vs insulin degludec (Tresiba): how do A1C and weight compare (SURPASS-3)?

Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

“Table 6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus insulin degludec, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Insulin Degludec MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT)a Population (N) 359 358 360 358 HbA1c (%) Baseline (mean) 8.1 8.2 8.2 8.2 Change at Week 52b -1.3 -1.9 -2.0 -2.1 Difference from insulin degludecb (95% CI) -- -0.6c (-0.7, -0.5) -0.8c (-0.9, -0.6) -0.9c (-1.0, -0.7) Patients (%) achieving HbA1c <7%d 58 79c 82c 83c Fasting Serum Glucose (mg/dL) Baseline (mean) 167 172 170 168 Change at Week 52b -51 -47 -50 -54 Body Weight (kg) Baseline (mean) 94.0 94.4 93.8 94.9 Change at Week 52b 1.9 -7.0 -9.6 -11.3 Difference from insulin degludecb (95% CI) -- -8.9c (-10.0, -7.8) -11.5c (-12.6, -10.4) -13.2c (-14.3, -12.1)” (opens the source at this quote in a new tab)

Note: Table 6 columns are insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

Mounjaro vs insulin glargine: how do A1C and weight compare (SURPASS-4)?

Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

“Table 7: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus insulin glargine, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Insulin Glargine MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N)a 998 328 326 337 HbA1c (%) Baseline (mean) 8.5 8.5 8.6 8.5 Change at Week 52b -1.4 -2.1 -2.3 -2.4 Difference from insulin glargineb (95% CI) -- -0.7c (-0.9, -0.6) -0.9c (-1.1, -0.8) -1.0c (-1.2, -0.9) Patients (%) achieving HbA1c <7%d 49 75c 83c 85c Fasting Serum Glucose (mg/dL) Baseline (mean) 168 172 176 174 Change at Week 52b -49 -44 -50 -55 Body Weight (kg) Baseline (mean) 90.2 90.3 90.6 90.0 Change at Week 52b 1.7 -6.4 -8.9 -10.6 Difference from insulin glargineb (95% CI) -- -8.1c (-8.9, -7.3) -10.6c (-11.4, -9.8) -12.2c (-13.0, -11.5)” (opens the source at this quote in a new tab)

Note: Table 7 columns are insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

How well does Mounjaro work when added to basal insulin (SURPASS-5)?

Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

“Table 8: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity. d Analyzed using logistic regression adjusted for baseline value and other stratification factors. Placebo MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 15 mg Modified Intent-to-Treat (mITT) Population (N)a 119 116 118 118 HbA1c (%) Baseline (mean) 8.4 8.3 8.4 8.2 Change at Week 40b -0.9 -2.1 -2.4 -2.3 Difference from placebob (95% CI) -- -1.2c (-1.5, -1.0) -1.5c (-1.8, -1.3) -1.5c (-1.7, -1.2) Patients (%) achieving HbA1c <7%d 35 87c 90c 85c Fasting Serum Glucose (mg/dL) Baseline (mean) 164 163 163 160 Change at Week 40b -39 -58 -64 -63 Difference from placebob (95% CI) -- -19c (-27, -11) -25c (-32, -17) -23c (-31, -16) Body Weight (kg) Baseline (mean) 94.2 95.8 94.6 96.0 Change at Week 40b 1.6 -5.4 -7.5 -8.8 Difference from placebob (95% CI) -- -7.1c (-8.7, -5.4) -9.1c (-10.7, -7.5) -10.5c (-12.1, -8.8)” (opens the source at this quote in a new tab)

Note: Table 8 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.

How much weight do adults lose on Mounjaro in type 2 diabetes trials?

Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

“SURPASS-1 through -5 evaluated the mean change in weight from baseline in adult patients with type 2 diabetes. SURPASS-1 studied Mounjaro monotherapy vs placebo over 40 weeks. The mean baseline weight was 191.8 lb, 190.0 lb, 188.5 lb, and 186.3 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=121) had a -14 lb change from baseline. Patients taking Mounjaro 10 mg (n=121) had a -15 lb change from baseline. Patients taking Mounjaro 15 mg (n=120) had a -17 lb change from baseline. Patients taking placebo (n=113) had a -2 lb change from baseline. SURPASS-2 studied Mounjaro as an add-on to metformin vs Ozempic 1 mg over 40 weeks. Ozempic 2 mg injection was not available at the time of the study. The mean baseline weight was 203.9 lb, 209.0 lb, 206.8 lb, and 206.6 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Ozempic 1 mg, respectively. Patients taking Mounjaro 5 mg (n=470) had a -17 lb change from baseline. Patients taking Mounjaro 10 mg (n=469) had a -21 lb change from baseline. Patients taking Mounjaro 15 mg (n=469) had a -25 lb change from baseline. Patients taking Ozempic 1 mg (n=468) had a -13 lb change from baseline. SURPASS-3 studied Mounjaro as an add-on to metformin plus or minus a sodium-glucose cotransporter-2 inhibitor vs Tresiba over 52 weeks. The mean baseline weight was 208.1 lb, 206.8 lb, 209.2 lb, and 207.2 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and Tresiba, respectively. Patients taking Mounjaro 5 mg (n=358) had a -15 lb change from baseline. Patients taking Mounjaro 10 mg (n=360) had a -21 lb change from baseline. Patients taking Mounjaro 15 mg (n=358) had a -25 lb change from baseline. Patients taking Tresiba (n=359) had a +4 lb change from baseline. SURPASS-4 studied Mounjaro as an add-on to 1-3 oral antihyperglycemic medications (metformin, sulfonylurea, sodium-glucose cotransporter-2 inhibitor) vs insulin glargine over 52 weeks. The mean baseline weight was 199.1 lb, 199.7 lb, 198.4 lb, and 198.9 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and insulin glargine, respectively. Patients taking Mounjaro 5 mg (n=328) had a -14 lb change from baseline. Patients taking Mounjaro 10 mg (n=326) had a -20 lb change from baseline. Patients taking Mounjaro 15 mg (n=337) had a -23 lb change from baseline. Patients taking insulin glargine (n=998) had a +4 lb change from baseline. SURPASS-5 studied Mounjaro as an add-on to basal insulin plus or minus metformin vs placebo over 40 weeks. The mean baseline weight was 211.2 lb, 208.6 lb, 211.6 lb, and 207.7 lb for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg, and placebo, respectively. Patients taking Mounjaro 5 mg (n=116) had a -12 lb change from baseline. Patients taking Mounjaro 10 mg (n=118) had a -17 lb change from baseline. Patients taking Mounjaro 15 mg (n=118) had a -19 lb change from baseline. Patients taking placebo (n=119) had a +4 lb change from baseline.” (opens the source at this quote in a new tab)

On the page, select: Image description

Note: The image description does not mark which results carry footnotes b and c. The Prescribing Information tables for SURPASS-1 through -5 give the same weight changes in kilograms with the difference from comparator and its 95% CI.

How much does Mounjaro lower A1C and BMI in children and teens (SURPASS-PEDS)?

Applies to Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

“Table 9: Results at Week 30 in a Trial of MOUNJARO Added to Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 6%, 0%, and 0% of patients randomized to placebo, MOUNJARO 5 mg, and 10 mg, respectively. At Week 30 the HbA1c endpoint was missing for 6%, 9%, and 18% of patients randomized to placebo, MOUNJARO 5 mg, and 10 mg, respectively. Missing Week 30 data were imputed using multiple imputation with placebo wash-out or with assumption of missing at random. b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (two-sided) for superiority versus placebo, adjusted for multiplicity. d Response in (%) is calculated by combining proportion of participants achieving target in imputed datasets using Rubin's rule. e p<0.01 (two-sided) for superiority versus placebo, adjusted for multiplicity. f Any missing values at baseline were imputed as missing at random. Placebo MOUNJARO 5 mg MOUNJARO 10 mg MOUNJARO 5 mg/10 mg pooled Modified Intent-to-Treat (mITT) Population (N)a 34 32 33 65 HbA1c (%) Baseline (mean) 8.0 8.2 7.9 8.1 Change at Week 30b -0.2 -1.9 -2.2 -2.0 Difference from placebob (95% CI) -- -1.7c (-2.4, -1.0) -2.0c (-2.7, -1.3) -1.8c (-2.4, -1.2) Patients (%) with HbA1c ≤6.5% at Week 30d 28 68c 81c 75c Fasting Serum Glucose (mg/dL) Baseline (mean) 156f 148f 152f 150f Change at Week 30b -5 -35 -51 -43 Difference from placebob (95% CI) -- -30e (-53, -8) -46c (-68, -24) -38c (-57, -19) BMI (kg/m2) Baseline (mean) 34.7 33.9 37.7 35.8 Percent Change at Week 30b -0.5 -6.9 -10.8 -8.8 Difference from placebo (%)b (95% CI) -- -6.4c (-9.5, -3.2) -10.3c (-13.5, -7.1) -8.3c (-11.0, -5.6)” (opens the source at this quote in a new tab)

Note: Table 9 columns are placebo, MOUNJARO 5 mg, 10 mg, and the 5 mg/10 mg pooled group, in that order.

Do A1C and BMI reductions on Mounjaro last 52 weeks in children (SURPASS-PEDS)?

Applies to Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

How much does Mounjaro lower A1C in early type 2 diabetes (SURPASS-EARLY)?

Applies to Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

Note: The clinical data page places an efficacy-estimand note after the graph description, while the video transcript identifies the -2.0% and -1.3% changes as treatment-regimen estimand results (the primary outcome). The page gives no between-group difference, confidence interval, or p-value. SURPASS-EARLY results are from the clinical data page of the Mounjaro HCP site, which cites Del Prato et al., Ann Intern Med 2026; the Mounjaro Prescribing Information does not describe this trial.

How much weight did people lose on Mounjaro in SURPASS-EARLY?

Applies to Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

Note: SURPASS-EARLY results are from the clinical data page of the Mounjaro HCP site; the Mounjaro Prescribing Information does not describe this trial.

Mounjaro SURPASS-EARLY: what treatments did the comparison group receive?

Applies to Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

How many people on Mounjaro met the combined A1C, weight, and hypoglycemia goal (SURPASS-EARLY)?

Applies to Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)

Note: SURPASS-EARLY results are from the clinical data page of the Mounjaro HCP site; the Mounjaro Prescribing Information does not describe this trial.